Introduction
Glioblastoma multiforme, the most common form of primary malignant brain tumors, is among the most aggressive and highly invasive human cancers. Despite surgery, radiotherapy and chemotherapy, the median survival time of 9-12 months post diagnosis has improved little over the last decades. 1 Gene therapy, including via an antiangiogenic approach, has provided hope. [2] [3] [4] [5] However, delivery with targeted specificity, at brain tumors or their vasculature, remains a major obstacle.
Endothelial progenitor cells (EPCs) have potential as spatial-specific delivery vehicles for tumor gene therapy. Since reported isolation of EPCs from peripheral blood in 1997, 6 they have been successfully derived from various sources such as embryonic stem cells, 7, 8 cord blood, 9, 10 bone marrow 11, 12 and peripheral blood. 13, 14 Their tropism for neovasculature has been demonstrated in animal models of ischemia and extracranial solid tumors. 10, 13, [15] [16] [17] This attractive characteristic of EPCs has been explored for cell-based tumor gene therapy. 4, 18 Solid tumor growth and metastases are dependent on the acquisition of adequate blood supply. Malignant gliomas are among the most vascularized tumors and the degree of vascularization correlates with prognosis. 19, 20 Recent studies have shown that tumors acquire their neovasculature by angiogenesis (development of pre-existing vessels) and also by vasculogenesis (formation of blood vessels from circulating EPCs, or angioblasts). 15, 21, 22 A strategy of incorporating EPCs carrying an antiangiogenic gene has potential to retard and destroy tumor vasculature. Such a targeted approach could minimize promiscuous effects caused by systemic administration of antiangiogenic agents.
However, there are no reports on tissue distribution of exogenous EPCs during the development of angiogenic intracranial tumors, an important issue for exploration of their potential in brain tumor gene therapy. Angiogenic factors involved in the growth of subcutaneously implanted tumor may differ from those of orthotopic counterparts. 23 It is thus relevant to investigate EPCs' tissue distribution under conditions of orthotopic intracranial brain tumors. Herein we studied the biodistribution of intravenously introduced EPCs in a SCID mouse intracranial glioma model, to determine the 'homing' specificity of EPCs.
EPCs were derived from human cord blood CD34 þ cells. Following in vitro characterization to define their identity, they were labeled and introduced into SCID mice, which had been intracranially implanted with human malignant glioma cells. Upon killing, the mouse brain and other vital organs were examined and the distribution of EPCs quantified. The results revealed significantly greater (Po0.001) incorporation of EPCs within intracranial brain tumors, compared with those of nontumor-bearing brain and other vital organs. This study demonstrated that systemically transplanted EPCs specifically 'homed' to intracranial gliomas. EPCs' in vivo tropism to orthotopic CNS solid tumors provides a potential platform for a spatialspecific brain tumor-targeted gene therapy.
Results

In vitro characterization of EPCs
Mononuclear cells (MNCs) were collected from cord blood by Ficoll gradient centrifugation. CD34 þ cells were isolated from MNCs by immunomagnetic separation. Fluorescence-activated cell sorting (FACS) analysis revealed the purity of isolated MNC CD34 þ as greater than 95% (Figure 1) .
To obtain EPCs, immunomagnetically purified CD34 þ cells were cultured with VEGF (10 ng/ml, R&D) and FGF2 (10 ng/ml, R&D). During the 2-week culturing period, the cells gradually attached onto fibronectincoated plates and adopted the shape of elongated cobblestones, a characteristic morphology of endothelial cells (Figure 2a ). Some cells in culture also formed cordlike structures spontaneously or on contact with a 'scratched' coarse surface of the plates (Figure 2b ), a functional feature of endothelial cells. RT-PCR and immunocytochemistry studies confirmed their EPC phenotype with expression of known endothelial cell markers including VE-cadherin, PECAM, CD34, Flk-1, Tie-1, Tie-2, low levels of Flt-1 ( Figure 3 ) and positive staining for P1H12 (Figure 2c ), an antiendothelial cellspecific antibody.
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EPCs' 'homing' specificity in a SCID mouse glioma model
Following in vitro characterization of EPCs derived from our culture system, we explored their in vivo 'homing' specificity using a SCID mouse glioma model. Figure  2d ). Negative control slides incubated with PE-conjugated mouse IgG1 showed no appreciable staining (data not shown).
Additionally, four separate control groups of mice were studied (Table 1 ). An equal number of CFSE-labeled EPCs were transplanted on experimental day seven (D 7 ) 
Discussion
Our study showed that systemically transplanted EPCs 'home' to orthotopic brain tumors with high specificity. This demonstrates vasculogenesis in brain tumor devel- Figure 3 RT-PCR analysis of endothelial cell-specific or -related gene expression from cultured EPCs. RT-PCR was performed using 0.5 mg template total RNA from cultured EPCs and specific primers for PECAM, Flt-1, Flk-1, tie-1, tie-2, CD34 and VE-cadherin cDNA. GAPDH was included as a positive control. The amplified samples were run on a 1% agarose gel and photographed. EPCs' homing specificity X-L Moore et al opment, a postnatal context, and highlights a potentially vulnerable tumor 'logistic supply train'.
To examine EPCs' tropism for orthotopic intracranial glioma, a SCID mouse intracranial glioma model was employed. In our model, implanted U87 human malignant glioma cells form microscopic tumors in approximately a week (about D 7 ) and the tumors grow exponentially 2 weeks (about D 14 ) after implantation. The general condition of tumor-bearing mice worsens 3 weeks (about D 21 ) after tumor implantation and most die by the 4th or 5th week (about D 28 -D 35 ) if not killed earlier. Development of intratumor neovasculature is the rule. The intratumor neovessel network could originate, to some degree, from recruited EPCs from the peripheral circulation and bone marrow. We hypothesized that intravenously administered exogenous EPCs could 'home' to brain tumor in accordance with neovasculature development. To test this hypothesis, we scheduled our EPC transplantation 1 week (D 7 ) after tumor cell implantation (D 0 ). Implanted U87 cells have formed microscopic tumors at this time point, and further growth is accompanied by formation of intratumor neovessels. If exogenous, transplanted, fluorescent EPCs could be subsequently identified in brain tumor sections, this would demonstrate exogenous EPCs' tropism to brain tumor. Furthermore, by quantifying and comparing the numbers of fluorescent, transplanted EPCs in brain tumors, nontumor involved brain and other vital organs, we would be able to assess the degree of relative 'homing' specificity of transplanted EPCs under orthotopic brain tumor conditions. Systemically transplanted EPCs 'homed' to intracranial brain tumors with high specificity. The number of transplanted EPCs was nearly 35 times greater in brain tumor sections compared with contralateral nontumorbearing brain, and was over 60 times greater when compared with other organs, except for spleen. Spleen contained nearly five times more EPCs, compared to other organs and this is consistent with its reticuloendothelial function; presumably, unincorporated transplanted EPCs would disintegrate and be cleared from the circulatory system, with residual fluorescence from disintegrated EPCs trapped in the spleen. Estimates based on number of EPCs per brain section, thickness of 25 Considering that we administered supraphysiological number of exogenous EPCs (10 6 /mouse), we expect that the kinetics would favor transplanted EPCs' incorporation into the developing vessel network in place of EPCs recruited from host bone marrow. This is consistent with Figure 2d wherein incorporated EPCs fluoresce throughout the tumor.
Histology analysis revealed that incorporation of systemically transplanted EPCs to brain tumors varied with the pathological appearance of the tumor. Sections prepared from D 14 killed experimental groups showed incorporation of transplanted EPCs, scattered throughout the entire tumor mass. In contrast, sections from D 21 killed experimental groups revealed EPC incorporation limited to the rim of the tumor mass. This phenomenon is concordant with pathologic characteristics of rapidly growing primary malignant glioma brain tumors and highlights the relevance of tumor microenvironment characteristics. A developing brain tumor at an early stage (such as before about D 7 -D 14 ) lacks a necrotic core. This pathologic characteristic develops later, typically with a highly angiogenic rim surrounding a central necrotic core. As we contemplate treatment systems such as EPC-delivered conditional activated gene therapy (eg, irradiation to activate a transcriptionally silent gene, 26 or suicide gene therapy with a prodrug system), 27 the different pattern of EPCs' 'homing' distribution between the D 14 and D 21 experimental groups in our study has implications. Our data suggest that EPC transplantation scheduled during the early stage of tumor development would achieve widely distributed incorporation all over the tumor mass, whereas EPC transplantation at a later stage might be regionally limited to the angiogenic rim of the tumor, with few 'homing' to the central necrotic core.
While our semiquantitative histology data suggested significant EPCs' incorporation into the brain tumor, general observation of the mice also supported this notion. EPC-transplanted tumor-bearing mice became more rapidly sickly in general appearance, with impaired coordination and behavior, than control groups. More mice died of tumor hemorrhage in EPC-transplanted groups than control groups. This implies that supraphysiological number of EPCs intravenously transplanted into the host circulatory system could potentially accelerate tumor growth. If incorporated EPCs were to be genetically engineered to carry an antiangiogenic gene or suicide gene, they could potentially function as 'Trojan horses' or 'suicide bombers' to transform a tumor 'strength' (robust incorporation of EPCs) into an 'Achilles heel'.
HUVECs obtained from Clonetics comprised one of our control groups. As cells change their phenotypes during prolonged culturing, we used HUVECs from early passages (opassage 6), with similar culture duration as for our transplanted EPCs so as to maximize consistency of HUVEC phenotype and to minimize potential variables associated with prolonged culturing. HUVECs did display affinity for brain tumors, with about five-fold-increased numbers in brain tumors as compared with other tissues. However, HUVEC numbers were significantly lower (about 12-fold) than EPCs, in brain tumors. Our data suggest that mature endothelial cells (ie, HUVECs) have 'homing' capability, to brain tumors; however, the less mature EPCs are likely to be superior candidates for further development of cellbased gene therapy. This is the first report of tissue distribution of intravenously transplanted EPCs in an orthotopic glioma mouse model. It provides evidence in support of the feasibility of EPCs as cell delivery vehicles for brain tumor gene therapy. 25 Combination with radiotherapy/ chemotherapy, and genetic manipulation such as a transcriptional silent TK gene controlled under a radioresponsive molecular switch 26 may help to realize this potential.
In conclusion, CD34 þ cells from human umbilical cord blood have been efficiently differentiated into EPCs. Following intravenous transplantation, these derived EPCs 'homed' to intracranial glioma with high specificity, constituting a platform for potential cell-delivered gene therapy. 'Engineered EPCs' have a range of potential applications, including 'programmable' gene therapy, targeted to inhibit/destroy brain tumors. EPCs' homing specificity X-L Moore et al
Materials and methods
Isolation of CD34
þ cells from cord blood
Human umbilical cord blood was collected, with maternal consent, in sterile blood bags (SC-200; Terumo Corp., Tokyo, Japan) containing citrate-dextrose solution as anticoagulant. Protocols for sampling human umbilical cord blood were approved by the Institutional Ethics Review Committee at Singapore General Hospital and the National Cancer Centre, Singapore. Fresh mononuclear cells (MNCs) were obtained from diluted cord blood (1:2 diluted with PBS) by density centrifugation using Ficoll-Paquet Plus (Amersham Pharmacia Biotech AB, Uppsala, Sweden). CD34 þ cells were then enriched by a magnetic bead separation method using a Direct CD34 Progenitor Cell Isolation Kit (MACS; Miltenyi Biotec, Auburn, USA), following the manufacturer's protocol. In brief, MNCs were reacted with an antihuman CD34 mAb coupled with microbeads. The beadattached cells (CD34 þ ) were separated on positiveselection columns set in a magnetic field (Miltenyi Biotec).
The purity of isolated CD34 þ cells was assessed by flow-cytometric analysis. Aliquots of pre-and postselected cells were incubated with FITC-conjugated anti-CD34 mAB (BD PharMingen, clone 581) and fixed in 2% paraformaldehyde for FACS analysis on FACSCalibur flow cytometer (Becton Dickinson Immunocytometry Systems). FITC-conjugated anti-mouse IgG (BD PharMingen, clone MOPC-21) was used for isotype control.
Cell culture and CSFE label
All cell culture media and reagents were purchased from Gibco-BRL, except those specified otherwise. The isolated CD34 þ cells were plated at a density of 5 Â 10 4 /cm 2 on human fibronectin-coated plastic plates (BIOCOAT; Becton-Dickinson), using a medium consisting of M199 supplemented with 20% FBS, 100 mM MEM nonessential amino acids, 1 mM MEM sodium pyruvate, 2 mM Lglutamine, 100 mg/ml streptomycin, 100 U/ml penicillin, 1 mM hydrocortisone (Sigma), 0.25 mg/ml amphotericin B, 20 U/ml heparin (Sigma), 50 mM b-mercaptoethanol, 10 ng/ml VEGF (R&D) and 10 ng/ml FGF2 (R&D). The plates were incubated at 371C in a humidified environment with 5% CO 2 . Media were changed every 3 days. At 14 days after initial plating, most cells adopted the shape of elongated cobblestones. They were detached from plates by incubation with 0.25% trypsin/2.5 mM EDTA at 371C for 10 min. The detached cells were labeled with CFSE (Molecular Probes). In brief, following 15 min incubation with CFSE (final conc. 20 mM) at 371C, cells were washed in 10 ml of PBS twice and then incubated in 10 ml of M199 medium for 2-3 h, changing medium every 30 min to ensure that unbound CFSE diffused out from cells completely to prevent subsequent dye leakage into cells adjacent to transplanted fluorescent EPCs. HUVECs were obtained from Clontics (Rockville, MD, USA) and cultured in a medium consisting of M199 supplemented with 20% FBS, 100 mM MEM nonessential amino acids, 1 mM MEM sodium pyruvate, 2 mM Lglutamine, 100 mg/ml streptomycin, 100 U/ml penicillin and 5 ng/ml VEGF (R&D). HUVECs in passages between 3 and 6 were labeled using CFSE before intravenous transplantation into mice. U87 human glioma cell line was obtained from ATCC and maintained in DMEM supplemented with 10% FBS, 100 mM MEM nonessential amino acids, 1 mM MEM sodium pyruvate, 2 mM L-glutamine, 100 mg/ml streptomycin and 100 U/ml penicillin. Regularly passaged U87 cells were passaged the day before implantation and trypsinized by incubation with 0.025% trypsin at 371C for 3-5 min. Viability of implanted cells was estimated by trypan blue exclusion assay.
Animal studies in vivo
Male SCID mice at 6-8 weeks of age were obtained from Animal Resources Centre, Australia, and held in an SPF animal facility of the Singapore National Cancer Centre. All animal experiments were performed in accordance with institutional guidelines. A total of 48 mice were divided into six groups (Table 1) .
To establish intracranial gliomas, mice were anesthetized by intraperitoneal (i.p.) administration of 100 mg of ketamine/5 mg of diazepam per kg of body weight. U87 human glioma cells (5000 cells resuspended in 5 ml of M199/mouse) were implanted into mice of experimental groups and HUVEC control groups by stereotactically guided injection over 3-5 min into the right forebrain (3 mm lateral and 1 mm anterior to bregma; depth 3-4 mm from dura).
At 7 days after U87 cell implantation, CFSE-labeled EPCs or HUVECs (1.0 Â 10 6 /mouse) were introduced into all 48 mice, via their tail veins. At 7 or 14 days after injection of EPCs or HUVECs, mice were killed. Following intracardiac perfusion with PBS and then 4% paraformaldehyde, organs were isolated, embedded in OCT compound (Tissue-Tek; Miles Inc., Eckhart, IN, USA), and snap-frozen in liquid nitrogen to examine biodistribution and localization of transplanted EPCs.
PCR analysis of RNA expression
Total cellular RNA was extracted from 0.5-1 Â 10 6 cultured cells with the use of Tri-reagent (MRC) as described by the manufacturer. Total RNA (0.5 mg) was treated with Superscript II (Gibco BRL) to generate cDNA using an oligo dT adaptor primer. Then, PCR amplification was performed for human PECAM, Flt-1, Flk-1, tie-1, tie-2, CD34 and VE-cadherin. The primers used are listed in Table 2 .
PCR amplification was performed under the following conditions: 30 cycles, 30 s at 941C, 30 s at 551C and 1 min at 721C. Before the first cycle, a denaturation step of 2 min at 941C was included, and after 30 cycles, the extension step was prolonged for 5 min at 721C. The amplified samples were run on a 1% agarose gel and photographed.
Immunocytochemistry and immunohistochemistry
Attached cells at day 14 of culture were subjected to immunocytochemistry to detect the expression of endothelial cell-specific antigen, P1H12. In brief, cells were grown on chamber slides and fixed with cold methanol. Endogenous peroxidase was inactivated with 3% hydrogen peroxide. Nonspecific mAb binding was blocked by incubation with 10% horse serum. PE-conjugated mAb directed against human CD146 (1:100 P1H12; Chemicon) and PE-conjugated mouse IgG 1 (as negative control) was applied respectively at room temperature for 2 hr. The Brain sections containing green fluorescent EPCs were also immunostained with PE-conjugated P1H12 (1:100, Chemicon) overnight at 41C to confirm the EPC identity. The mAb was mouse IgG 1 , and thus negative control slides were incubated with PE-conjugated mouse IgG 1 .
Statistics
All data were subjected to one-way ANOVA analysis followed by the Bonferroni's multiple comparison test 27 for comparison between two means. Probabilities less than 0.05 were considered to be statistically significant. The risk of detecting contaminating genomic DNA in the RT-PCR analysis was minimized by designing primer pairs spanning introns, using known genomic sequences.
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